Switzerland's Biotech Surge: Windward Bio Secures Funding, Forges Global Drug Deal Amidst Venturelab's Record Year
January 12, 2026, 3:31 pm
Swiss innovation is surging. Venturelab, a key accelerator, empowered over 6,700 entrepreneurs in 2025. It propelled Swiss startups to raise billions in funding. Biotech leader Windward Bio exemplified this success. The company secured a significant CHF 160 million. This placed it among the year's top funding recipients. Windward Bio also finalized a major licensing agreement. This deal, valued up to $700 million, targets WIN027. WIN027 is a clinical-stage, long-acting bispecific antibody. It inhibits TSLP and IL-13. This promises groundbreaking therapy for respiratory and dermatological conditions. Think asthma, COPD, atopic dermatitis. Switzerland's dynamic ecosystem fosters global healthcare advancements and robust venture capital growth.
Switzerland solidifies its position as a global innovation hub. Its startup ecosystem demonstrates remarkable vitality. Organizations like Venturelab are central to this success. Venturelab reported a record-breaking year in 2025. It delivered extensive training and support. Thousands of entrepreneurs benefited directly.
Venturelab's mission is clear. It builds world-class startups. The year 2025 saw 544 days of training, workshops, and international programs. These efforts reached 6,700 inspiring entrepreneurs. This dedication pays dividends. Swiss startups collectively raised billions. This funding influx surpassed previous year's totals.
A core component of Venturelab's strategy is direct funding. The Venture Kick program supports nascent projects. In 2025, 130 new projects received backing. This translated into 247 individual funding "kicks." A total of CHF 8.32 million was allocated. This seed capital is vital for early-stage companies.
Beyond initial funding, Venturelab fosters growth. Innosuisse Entrepreneurship Training reached thousands. It helped startups scale operations. International exposure is another critical element. The Swiss National Startup Team conducted global roadshows. Founders connected with investors in Silicon Valley, Boston, London, and Munich. These connections are invaluable. They open doors to global markets and capital.
The annual Top100 Swiss Startup Award marked its 15th anniversary. This event celebrates the nation's most promising ventures. Handpicked investors attended the Top100 Investor Summit. They represented over CHF 20 billion in venture capital. This summit provides a crucial platform. It links innovators with significant investment potential.
Swiss startups attracted substantial investment in 2025. The fundraising momentum showed no signs of slowing. Several companies secured nine-figure rounds. Energy Vault led the pack with over CHF 241 million. Climeworks followed, raising CHF 130 million. These figures highlight investor confidence.
One prominent success story is Windward Bio. This clinical-stage biotechnology company launched in early 2025. It started strong with a $200 million Series A round. This initial funding underscored investor belief. Windward Bio aims to develop long-acting bispecific antibodies. These therapies target validated biology. They focus on respiratory and dermatological conditions.
Windward Bio further bolstered its financial standing. It secured an additional CHF 160 million in 2025. This significant raise placed it second among Switzerland's largest funding rounds. Its inclusion on Venturelab's top funding list demonstrates its rapid ascent. This capital infusion empowers its ambitious pipeline development.
The company's strategic growth extends to licensing deals. Windward Bio, via its affiliate LE2025 Therapeutics AG, inked a major agreement. This partnership is with Qyuns Therapeutics. Qyuns Therapeutics is a Chinese biotechnology unicorn. It specializes in antibody drugs for autoimmune and allergic diseases. This collaboration expands Windward Bio's clinical pipeline.
The centerpiece of this deal is WIN027. This drug candidate was previously known as QX027N. WIN027 is a clinical-stage bispecific monoclonal antibody. It targets thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13). Both TSLP and IL-13 are well-validated targets. They play crucial roles in immunological conditions.
WIN027 is currently undergoing Phase 1 clinical trials. These trials assess its safety profile. The antibody is a humanized IgG1. It exhibits high affinity for both TSLP and IL-13. A key design feature is its extended half-life. This engineering enables less frequent dosing. This offers enhanced patient convenience.
The dual inhibition strategy of WIN027 is innovative. It promises a new standard of efficacy. This could benefit patients with various conditions. These include asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. These diseases represent significant unmet medical needs.
Under the licensing terms, Windward Bio gains extensive rights. It holds exclusive rights to develop, manufacture, and commercialize WIN027. This applies to all territories outside of China, Taiwan, Hong Kong, and Macau. This broad market access is strategically crucial.
The total value of this landmark deal is substantial. It reaches up to $700 million. This figure comprises an upfront payment and equity interest. It also includes milestone payments. These payments are contingent on specific development, regulatory, and commercial achievements. Tiered royalties on future product sales also form part of the agreement.
This marks Windward Bio's second licensing deal in 2025. It underscores a clear strategic focus. The company prioritizes pipeline expansion. It aims to accelerate differentiated therapies. Patients living with serious immunological diseases stand to benefit.
The success of companies like Windward Bio reflects a broader trend. Switzerland’s robust infrastructure supports biotech innovation. Its academic institutions are strong. Its government provides supportive policies. The venture capital ecosystem is maturing. All these factors combine. They create fertile ground for medical breakthroughs.
Venturelab’s role in this ecosystem is undeniable. It provides foundational support. It connects startups with essential resources. It prepares them for global competition. Its network of partners is extensive. These partners include major corporations and financial institutions. This collective effort propels Swiss innovation forward.
Looking ahead, Venturelab intends to continue its mission. It will support the next generation of world-class startups. The achievements of 2025 set a high bar. They demonstrate the potential of focused entrepreneurship. Switzerland’s biotech sector is poised for further growth. It promises continued contributions to global health. The world watches for more Swiss-made innovation.
Switzerland solidifies its position as a global innovation hub. Its startup ecosystem demonstrates remarkable vitality. Organizations like Venturelab are central to this success. Venturelab reported a record-breaking year in 2025. It delivered extensive training and support. Thousands of entrepreneurs benefited directly.
Venturelab's mission is clear. It builds world-class startups. The year 2025 saw 544 days of training, workshops, and international programs. These efforts reached 6,700 inspiring entrepreneurs. This dedication pays dividends. Swiss startups collectively raised billions. This funding influx surpassed previous year's totals.
A core component of Venturelab's strategy is direct funding. The Venture Kick program supports nascent projects. In 2025, 130 new projects received backing. This translated into 247 individual funding "kicks." A total of CHF 8.32 million was allocated. This seed capital is vital for early-stage companies.
Beyond initial funding, Venturelab fosters growth. Innosuisse Entrepreneurship Training reached thousands. It helped startups scale operations. International exposure is another critical element. The Swiss National Startup Team conducted global roadshows. Founders connected with investors in Silicon Valley, Boston, London, and Munich. These connections are invaluable. They open doors to global markets and capital.
The annual Top100 Swiss Startup Award marked its 15th anniversary. This event celebrates the nation's most promising ventures. Handpicked investors attended the Top100 Investor Summit. They represented over CHF 20 billion in venture capital. This summit provides a crucial platform. It links innovators with significant investment potential.
Swiss startups attracted substantial investment in 2025. The fundraising momentum showed no signs of slowing. Several companies secured nine-figure rounds. Energy Vault led the pack with over CHF 241 million. Climeworks followed, raising CHF 130 million. These figures highlight investor confidence.
One prominent success story is Windward Bio. This clinical-stage biotechnology company launched in early 2025. It started strong with a $200 million Series A round. This initial funding underscored investor belief. Windward Bio aims to develop long-acting bispecific antibodies. These therapies target validated biology. They focus on respiratory and dermatological conditions.
Windward Bio further bolstered its financial standing. It secured an additional CHF 160 million in 2025. This significant raise placed it second among Switzerland's largest funding rounds. Its inclusion on Venturelab's top funding list demonstrates its rapid ascent. This capital infusion empowers its ambitious pipeline development.
The company's strategic growth extends to licensing deals. Windward Bio, via its affiliate LE2025 Therapeutics AG, inked a major agreement. This partnership is with Qyuns Therapeutics. Qyuns Therapeutics is a Chinese biotechnology unicorn. It specializes in antibody drugs for autoimmune and allergic diseases. This collaboration expands Windward Bio's clinical pipeline.
The centerpiece of this deal is WIN027. This drug candidate was previously known as QX027N. WIN027 is a clinical-stage bispecific monoclonal antibody. It targets thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13). Both TSLP and IL-13 are well-validated targets. They play crucial roles in immunological conditions.
WIN027 is currently undergoing Phase 1 clinical trials. These trials assess its safety profile. The antibody is a humanized IgG1. It exhibits high affinity for both TSLP and IL-13. A key design feature is its extended half-life. This engineering enables less frequent dosing. This offers enhanced patient convenience.
The dual inhibition strategy of WIN027 is innovative. It promises a new standard of efficacy. This could benefit patients with various conditions. These include asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. These diseases represent significant unmet medical needs.
Under the licensing terms, Windward Bio gains extensive rights. It holds exclusive rights to develop, manufacture, and commercialize WIN027. This applies to all territories outside of China, Taiwan, Hong Kong, and Macau. This broad market access is strategically crucial.
The total value of this landmark deal is substantial. It reaches up to $700 million. This figure comprises an upfront payment and equity interest. It also includes milestone payments. These payments are contingent on specific development, regulatory, and commercial achievements. Tiered royalties on future product sales also form part of the agreement.
This marks Windward Bio's second licensing deal in 2025. It underscores a clear strategic focus. The company prioritizes pipeline expansion. It aims to accelerate differentiated therapies. Patients living with serious immunological diseases stand to benefit.
The success of companies like Windward Bio reflects a broader trend. Switzerland’s robust infrastructure supports biotech innovation. Its academic institutions are strong. Its government provides supportive policies. The venture capital ecosystem is maturing. All these factors combine. They create fertile ground for medical breakthroughs.
Venturelab’s role in this ecosystem is undeniable. It provides foundational support. It connects startups with essential resources. It prepares them for global competition. Its network of partners is extensive. These partners include major corporations and financial institutions. This collective effort propels Swiss innovation forward.
Looking ahead, Venturelab intends to continue its mission. It will support the next generation of world-class startups. The achievements of 2025 set a high bar. They demonstrate the potential of focused entrepreneurship. Switzerland’s biotech sector is poised for further growth. It promises continued contributions to global health. The world watches for more Swiss-made innovation.